You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾和諾德提早一年在印度推「減肥神藥」 截擊禮來(LLY.US)
阿思達克 06-25 12:47
《日經亞洲》報道,「減肥神藥」生產商、丹麥藥廠諾和諾德(Novo Nordisk)昨日(24日)在印度推出其Wegovy減重藥物,較原定2026年推出的計劃提早一年。此次推出涵蓋五種不同劑量,價格從每週約4,366盧比(約50美元)的0.25毫克劑量,到每週約6,503盧比的2.4毫克劑量,顯著低於美國2.4毫克每週337美元的價格。 此次提前上市發生在美國競爭對手禮來(LLY.US)今年3月在印度推出其受歡迎的減重藥Mounjaro(tirzepatide)之後。Mounjaro的2.5毫克每週劑量價格約3,500盧比。據《彭博》報道,Mounjaro在印度5月銷售額按月增長60%,達到1.26億盧比(約146.6萬美元)。 據《刺針》醫學期刊的研究報告,印度的肥胖人口預計將從2021年的1.8億增加到2050年的4.5億,成為僅次於中國的全球第二大肥胖市場。 諾和諾德去年11月亦在中國內地推出了Wegovy,該市場同樣面臨來自禮來Mounjaro的競爭。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account